Australia's largest stock trading and investment forum Australia's #1 stock forum

Scomo dribbled nothing but lies, and your point is?

First 207 Last

reggie78

2,167 Posts.

571

26/01/24

19:14

Post #: 72083163

Originally posted by pints: ↑
Albo is a monstrous liar.
However, on this issue he has taken the popular way to appeal to many voters, as I said before.

Peter Dutton on Anthony 'Bullshit' Albanese.
Thursday, 25 January 2024

Before the last election, Anthony Albanese promised he would ‘under no circumstances’ cancel the Coalition’s stage three tax cuts, due to commence on 1 July this year.

He promised Australians that they could trust him to keep his promise because,"My word is my bond".

Now, after days of leaks and speculation, the Prime Minister confirmedhis word is worth nothing.

Today, at the National Press Club, the Prime Minister broke his promise and betrayed the Australian people.

Anthony Albanese has looked Australians in the eye and knowingly and repeatedly lied to them.

He has committed a breach of trust on a scale not seen since Julia Gillard’s infamous ‘No Carbon Tax’ promise.

If the Prime Minister can perpetrate such a huge lie, how can anyone ever believe anything he says, ever again?

Today’s announcement has left Australians with more questions than answers.

But one thing is clear –Anthony Albanese cannot be trusted.
Regards,

Peter Dutton
Expand
Scomo dribbled nothing but lies, and your point is?

5 Upvote

Top Stories

TKM

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

HZR

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

TNC

True North increases silver metal at QLD's Vero deposit by 20%

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Bitcoin: Current State of Play & Where to Next | Swyftx

Emerald & Azure score Digger & Dealer awards

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Revolutionary inverter technology leads the clean energy charge

NEU

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

There are more pages in this discussion • 132 more messages in this thread...

First 207 Last

Scomo dribbled nothing but lies, and your point is?

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

True North increases silver metal at QLD's Vero deposit by 20%

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Bitcoin: Current State of Play & Where to Next | Swyftx

Emerald & Azure score Digger & Dealer awards

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Revolutionary inverter technology leads the clean energy charge

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Featured News

Featured News

Scomo dribbled nothing but lies, and your point is?

Top Stories

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

True North increases silver metal at QLD's Vero deposit by 20%

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Bitcoin: Current State of Play & Where to Next | Swyftx

Emerald & Azure score Digger & Dealer awards

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Revolutionary inverter technology leads the clean energy charge

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Featured News

Featured News